AIV Logo AIV Assistant

Loading...

Logo AEON Biopharma, Inc. - AEON Open AEON Biopharma, Inc. in new tab

1.00 USD
P/E
0.00
EPS
-13.91
P/B
-0.62
Beta
0.74

0.9989 USD

0.999 USD

Daily: -1.10%
Key Metrics

Earnings date: Nov. 12, 2025

P/E: 0.00

EPS: -13.91

Book Value: -1.37

Price to Book: -0.62

% Insiders: 19.110%

Estimates

Forward P/E: -1.23

Forward EPS: -0.69

DCF Valuation

Tweak assumptions to recompute fair value for AEON Biopharma, Inc. (AEON)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Logo About AEON Biopharma, Inc. - (AEON)

Website: https://www.aeonbiopharma.com

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Exchange Ticker
None AEON

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Feb. 26, 2025 0.010000
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion